Search Results 2621-2630 of 17718 for rheumatoid arthritis

  1. Rucaparib (oral route) - Mayo Clinic

    This medicine may make your skin more sensitive to sunlight. Use sunscreen or sunblock lotion and lip balm with a sun protection factor (SPF) of at least 30 on ...

  2. Targeted Drug Therapy Clinical Trials - Mayo Clinic Research

    ... factor receptor 2 (FGFR2). Ponatinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Linsitinib or ...

  3. A Study to Evaluate the Safety, Tolerability, Drug/Body Interactions, and Activity of Oradoxel for Patients with Advanced Malignancies - Mayo Clinic

    Adequate hematologic status as demonstrated by not requiring transfusion support or granulocyte-colony stimulating factor (G-CSF) to maintain an absolute ...

  4. Neck pain - Doctors and departments - Mayo Clinic

    Thompson, M.D.. Physiatrist. Rochester, MN. Areas of focus: Electromyography, Amputation rehabilitation, Arthritis rehabilitation, Nerve conduction study, ...

  5. Publications - Luca Stocchi, M.D. - Mayo Clinic

    ... factor agents in postoperative recurrent Crohn's disease following ileocolonic resection. Int J Colorectal Dis. 2016 Nov; 31 (11):1751-1758 Epub 2016 July ...

  6. Genetics of Atherosclerosis - Atherosclerosis and Lipid Genomics Laboratory - Mayo Clinic Research

    Family history as a risk factor for peripheral arterial disease. Am J Cardiol. 2014 Sep 15;114(6):928-32. Epub 2014 Jul 2. [PMID: 25107577; PMC4206951] ...

  7. Publications - Oana M. Dumitrascu, M.D. - Mayo Clinic

    Differential Expression of Vascular Endothelial Growth Factor-A165 Isoforms Between Intracranial Atherosclerosis and Moyamoya Disease. J Stroke Cerebrovasc ...

  8. COVID Controls - Mayo Clinic

    Participation eligibility · Active persistent COVID infection. · < 40 kg in weight have a known history of any condition or factor judged by the investigator to ...

  9. A Phase 1 Study Evaluating the Safety, PK, and Clinical Effects of PT-112 in Subjects With Advanced Solid Tumors

    ... factor treatment (e.g., erythropoietin) within 14 days before initiation of study drug. Human immunodeficiency virus or acquired immunodeficiency syndrome ...

  10. A Study to Evaluate Lasofoxifene versus Fulvestrant in Advanced or Metastatic ER+/HER2− Breast Cancer Patients with an ESR1 Mutation - Mayo Clinic

    ... factor 2 negative (HER2−) breast cancer with an ESR1 mutation. Participation eligibility. Participant eligibility includes age, gender, type and stage of ...